AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors
Status:
Completed
Trial end date:
2019-10-16
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 1b, multi-centre, dose escalation study is to find the maximum
tolerated dose (MTD) of AZD1775 combined with olaparib in patients with refractory solid
tumours